by mm-red | Jul 29, 2020
Background: Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and...
by mm-red | Jun 6, 2020
Background: The For Angioedema Subcutaneous Treatment (FAST)-2, a phase III, double-blind, randomized, multicenter, placebo-controlled study (ClinicalTri als.gov identifier: NCT00500656), established the efficacy and safety of single injections of icatibant, a...
Recent Comments